1 research outputs found
A combined computational and functional approach identifies IGF2BP2 as a driver of chemoresistance in a wide array of pre-clinical models of colorectal cancer
Aim Chemoresistance is a major cause of treatment failure in colorectal cancer (CRC) therapy. In this study, the
impact of the IGF2BP family of RNA-binding proteins on CRC chemoresistance was investigated using in silico, in vitro,
and in vivo approaches.
Methods Gene expression data from a well-characterized cohort and publicly available cross-linking immunoprecipi‑
tation sequencing (CLIP-Seq) data were collected. Resistance to chemotherapeutics was assessed in patient-derived
xenografts (PDXs) and patient-derived organoids (PDOs). Functional studies were performed in 2D and 3D cell culture
models, including proliferation, spheroid growth, and mitochondrial respiration analyses.
Results We identifed IGF2BP2 as the most abundant IGF2BP in primary and metastastatic CRC, correlating with
tumor stage in patient samples and tumor growth in PDXs. IGF2BP2 expression in primary tumor tissue was signif‑
cantly associated with resistance to selumetinib, geftinib, and regorafenib in PDOs and to 5-fuorouracil and oxalipl‑
atin in PDX in vivo. IGF2BP2 knockout (KO) HCT116 cells were more susceptible to regorafenib in 2D and to oxaliplatin,
selumitinib, and nintedanib in 3D cell culture. Further, a bioinformatic analysis using CLIP data suggested stabiliza‑
tion of target transcripts in primary and metastatic tumors. Measurement of oxygen consumption rate (OCR) and
extracellular acidifcation rate (ECAR) revealed a decreased basal OCR and an increase in glycolytic ATP production
rate in IGF2BP2 KO. In addition, real-time reverse transcriptase polymerase chain reaction (qPCR) analysis confrmed
decreased expression of genes of the respiratory chain complex I, complex IV, and the outer mitochondrial membrane
in IGF2BP2 KO cells. Conclusions IGF2BP2 correlates with CRC tumor growth in vivo and promotes chemoresistance by altering mito‑
chondrial respiratory chain metabolism. As a druggable target, IGF2BP2 could be used in future CRC therapy to
overcome CRC chemoresistance